Autonomix Medical

Home
United States
The Woodlands, TX
Autonomix Medical

Directions Website

Autonomix (Nasdaq: AMIX) is focused on advancing innovative technologies to revolutionize how diseases involving the nervous system are diagnosed and treated.

11/06/2026

Our CEO, Brad Hauser, recently presented ""Illuminating the Nervous System With Transvascular Precision-Guided Technology"" at the recent TCT 2026 forum.

It was a privilege to be part of the global cardiovascular community, sharing ideas and contributing to the conversations shaping the future of interventional medicine.

10/02/2026

Brad Hauser, Chief Executive Officer of Autonomix Medical, comments on the issuance of a Canadian patent covering Autonomix’s transvascular intervention platform across multiple nerve-targeted therapies: https://bit.ly/4xTQyB9

10/02/2026

Autonomix's new Canadian patent expands protection for catheter-based technologies enabling transvascular access, treatment guidance, adaptive treatment delivery, and real-time procedural validation beyond the lumen wall. Read more about Autonomix's growing patent portfolio: https://bit.ly/4xTQyB9

10/02/2026

Autonomix today announced that the Canadian Intellectual Property Office (CIPO) has issued Canadian Patent No. 3,183,802, titled, "Systems, Methods, and Devices for Monitoring and Treatment of Tissues Within and/or Through a Lumen Wall." The patent further reinforces Autonomix’s transvascular intervention platform across multiple nerve-targeted therapies.

Read more: https://bit.ly/4xTQyB9

09/30/2026

“This FDA interaction gives us greater clarity on the work required to pursue an initial U.S. clearance and represents a significant milestone in advancing our proprietary technology toward the U.S. market,” said Brad Hauser, CEO of Autonomix. Read his full comments: https://bit.ly/4hUwppN

09/30/2026

Autonomix's FDA pre-submission feedback supports a Class II strategy, leveraging substantial equivalence to a previously cleared device, positioning the Company for potential initial U.S. clearance of its standalone sensing platform in approximately 15 months. Read more: https://bit.ly/4hUwppN

09/30/2026

Autonomix today announced the successful completion of a pre-submission meeting with the U.S. Food and Drug Administration (FDA) regarding the Company’s recently announced standalone transvascular sensing platform, which is designed to detect and differentiate faint biological signals. Read more: https://bit.ly/4hUwppN

09/24/2026

"This European patent represents another important step in expanding our global intellectual property footprint," said Brad Hauser, Chief Executive Officer of Autonomix. Read more about Autonomix's international intellectual property portfolio: https://bit.ly/47gbqrl

09/24/2026

Autonomix's new European patent strengthens protection for proprietary autonomic nervous system assessment technologies, further expanding Company's international patent portfolio. Learn more about the patent: https://bit.ly/47gbqrl

Address

The Woodlands, TX
77380

Website

http://autonomix.com/

Alerts

Be the first to know and let us send you an email when Autonomix Medical posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.